Hemogram Parameter Changes With Sepsis Filter

April 21, 2025 updated by: Samsun University

Change in Hemogram-Derived Ratios With Sepsis Filters:A Retrospective Cohort Study in the Intensive Care Unit

Hemodiafiltration is initiated in hemodynamically unstable patients in intensive care units. In some patients, additional devices called cytokine filters or sepsis filters are added to remove inflammatory cytokines. Data obtained from hemograms, such as platelet lymphocytosis ratio, are used in the diagnosis or prognosis of many diseases. This study focuses on the change in hemogram rates in patients who received hemofiltration and sepsis filters.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

92

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Istinye University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Hemodiafiltration is started on patients in intensive care units. This study focuses on the change in hemogram rates in patients who underwent hemofiltration and had sepsis filters placed.

Description

Inclusion Criteria:

  • Data of patients who were monitored in the Intensive Care between January 2020 and December 2022 and who were applied sepsis filters

Exclusion Criteria:

  • -Patients who underwent hemodiafiltration with sepsis filter but could not be followed for 72 hours (death, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet lymphocyte ratio change
Time Frame: up to 72 hours
Change in platelet lymphocyte ratio measured from hemogram at the beginning (day 0) and the ratio calculated from the sample taken on day 3 in patients undergoing hemodiafiltration with sepsis filter
up to 72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in the other ratios derived from complete blood cell count
Time Frame: up to 72 hours
Changes in hemogram derivation ratios measured from the hemogram at the beginning (day 0) and the ratio calculated from the sample taken on day 3 in patients who underwent hemodiafiltration with sepsis filter
up to 72 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsun University

Investigators

  • Study Chair: Erkan Bayram, Istınye university faculity of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2024

Primary Completion (Actual)

February 1, 2024

Study Completion (Actual)

February 1, 2024

Study Registration Dates

First Submitted

April 21, 2025

First Submitted That Met QC Criteria

April 21, 2025

First Posted (Actual)

April 29, 2025

Study Record Updates

Last Update Posted (Actual)

April 29, 2025

Last Update Submitted That Met QC Criteria

April 21, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Istinye University

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe